Corteva, Inc. $CTVA Shares Bought by Crossmark Global Holdings Inc.

Key Points

• Crossmark Global Holdings Inc. boosted its stake in Corteva by 169.4%, buying 83,000 shares to hold 132,002 shares valued at about $8.93 million, and institutional investors now own roughly 81.54% of the company.
• Corteva reported quarterly EPS of $0.22 (in line with estimates) but revenue of $3.91 billion missed expectations ($4.23 billion) and was down 1.7% year‑over‑year, while management set FY2026 EPS guidance of 3.45–3.70.
• The company announced a quarterly dividend of $0.18 (annualized $0.72, yield ~0.9%, ex‑dividend March 2), and insider Brian Titus recently sold 8,311 shares, cutting his stake by about 50.7%.

Crossmark Global Holdings Inc. lifted its holdings in shares of Corteva, Inc. (NYSE:CTVA - Free Report) by 169.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 132,002 shares of the company's stock after purchasing an additional 83,000 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in Corteva were worth $8,927,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Brighton Jones LLC boosted its position in Corteva by 307.2% in the 4th quarter. Brighton Jones LLC now owns 15,588 shares of the company's stock valued at $888,000 after buying an additional 11,760 shares during the period. Woodline Partners LP increased its position in shares of Corteva by 40.3% during the first quarter. Woodline Partners LP now owns 57,919 shares of the company's stock worth $3,645,000 after acquiring an additional 16,644 shares during the period. Atlantic Union Bankshares Corp purchased a new stake in shares of Corteva during the second quarter worth $1,386,000. Resona Asset Management Co. Ltd. raised its stake in shares of Corteva by 3.9% in the second quarter. Resona Asset Management Co. Ltd. now owns 226,584 shares of the company's stock valued at $16,883,000 after acquiring an additional 8,606 shares in the last quarter. Finally, Andra AP fonden acquired a new stake in shares of Corteva in the second quarter valued at $3,533,000. Hedge funds and other institutional investors own 81.54% of the company's stock.

Analyst Upgrades and Downgrades

CTVA has been the subject of several analyst reports. Oppenheimer set a $86.00 target price on Corteva in a research note on Thursday, February 5th. Citigroup increased their price target on Corteva from $74.00 to $80.00 and gave the company a "neutral" rating in a research report on Thursday, February 5th. Mizuho lifted their price objective on Corteva from $80.00 to $82.00 and gave the company an "outperform" rating in a research note on Tuesday, February 17th. Weiss Ratings reissued a "hold (c-)" rating on shares of Corteva in a research report on Monday, December 29th. Finally, Rothschild & Co Redburn cut their target price on shares of Corteva from $71.00 to $65.00 and set a "neutral" rating on the stock in a research note on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $82.80.

Corteva Stock Performance

NYSE:CTVA opened at $76.95 on Friday. The firm has a market capitalization of $51.75 billion, a PE ratio of 48.70, a price-to-earnings-growth ratio of 2.62 and a beta of 0.72. The business's fifty day moving average price is $73.00 and its 200 day moving average price is $69.05. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 0.96. Corteva, Inc. has a 12 month low of $53.40 and a 12 month high of $80.90.

Corteva (NYSE:CTVA - Get Free Report) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $0.22 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.22. The company had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $4.23 billion. Corteva had a return on equity of 9.06% and a net margin of 6.29%.Corteva's revenue for the quarter was down 1.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.32 EPS. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, sell-side analysts anticipate that Corteva, Inc. will post 2.96 earnings per share for the current fiscal year.

Corteva Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 16th. Investors of record on Monday, March 2nd will be paid a dividend of $0.18 per share. The ex-dividend date is Monday, March 2nd. This represents a $0.72 annualized dividend and a yield of 0.9%. Corteva's payout ratio is presently 45.57%.

Insiders Place Their Bets

In related news, insider Brian Titus sold 8,311 shares of the company's stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $76.55, for a total value of $636,207.05. Following the completion of the transaction, the insider directly owned 8,090 shares of the company's stock, valued at $619,289.50. This represents a 50.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.14% of the stock is currently owned by insiders.

About Corteva

Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.